211 422

Cited 9 times in

Cited 9 times in

Achievement of LDL-C targets defined by ESC/EAS (2011) guidelines in risk-stratified Korean patients with dyslipidemia receiving lipid-modifying treatments

DC Field Value Language
dc.contributor.authorYang, Ye Seul-
dc.contributor.authorLee, Seo Young-
dc.contributor.authorKim, Jung-Sun-
dc.contributor.authorChoi, Kyung Mook-
dc.contributor.authorLee, Kang Wook-
dc.contributor.authorLee, Sang-Chol-
dc.contributor.authorCho, Jung Rae-
dc.contributor.authorOh, Seung-Jin-
dc.contributor.authorKim, Ji-Hyun-
dc.contributor.authorChoi, Sung Hee-
dc.date.accessioned2021-09-29T02:26:19Z-
dc.date.available2021-09-29T02:26:19Z-
dc.date.created2021-03-17-
dc.date.issued2020-06-
dc.identifier.issn2093-596X-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/184894-
dc.description.abstractBackground: This study assessed the proportion of risk-stratified Korean patients with dyslipidemia achieving their low-density lipoprotein cholesterol (LDL-C) targets as defined by the European Society of Cardiology/European Atherosclerosis Society (ESC/ EAS) (2011) guidelines while receiving lipid-modifying treatments (LMTs). Methods: In this multicenter, cross-sectional, observational study, we evaluated data from Korean patients aged ≥19 years who were receiving LMTs for ≥3 months and had an LDL-C value within the previous 12 months on the same LMT. Data were collected for demographics, cardiovascular (CV) risk factors, medical history, and healthcare consumption. Patients were risk-stratified according to the ESC Systematic COronary Risk Evaluation (SCORE) chart and LDL-C target achievement rate was assessed. Results: Guideline-based risk-stratification of the 1,034 patients showed the majority (72.2%) to be in the very high-risk category. Investigators' assessment of risk was underestimated in 71.6% compared to ESC/EAS guidelines. Overall LDL-C target achievement rate was 44.3%; target achievement was the highest (66.0%) in moderate-risk patients and the lowest (39.0%) in very high-risk patients. Overall 97.1% patients were receiving statin therapy, mostly as a single-agent (89.2%). High-intensity statins and the highest permissible dose of high-intensity statins had been prescribed to only 9.1% and 7.3% patients in the very high-risk group, respectively. Physician satisfaction with patients' LDL-C levels was the primary reason for non-intensification of statin therapy. Conclusion: Achievement of target LDL-C level is suboptimal in Korean patients with dyslipidemia, especially in those at very high-risk of CV events. Current practices in LMTs need to be improved based on precise CV risk evaluation posed by dyslipidemia. © 2020 Korean Endocrine Society-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherKorean Endocrine Society-
dc.relation.isPartOfEndocrinology and Metabolism(대한내분비학회지)-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleAchievement of LDL-C targets defined by ESC/EAS (2011) guidelines in risk-stratified Korean patients with dyslipidemia receiving lipid-modifying treatments-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorYang, Ye Seul-
dc.contributor.googleauthorLee, Seo Young-
dc.contributor.googleauthorKim, Jung-Sun-
dc.contributor.googleauthorChoi, Kyung Mook-
dc.contributor.googleauthorLee, Kang Wook-
dc.contributor.googleauthorLee, Sang-Chol-
dc.contributor.googleauthorCho, Jung Rae-
dc.contributor.googleauthorOh, Seung-Jin-
dc.contributor.googleauthorKim, Ji-Hyun-
dc.contributor.googleauthorChoi, Sung Hee-
dc.identifier.doi10.3803/EnM.2020.35.2.367-
dc.relation.journalcodeJ00773-
dc.identifier.eissn2093-5978-
dc.subject.keywordCholesterol-
dc.subject.keywordDyslipidemias-
dc.subject.keywordHydroxymethylglutaryl-CoA reductase inhibitors-
dc.subject.keywordKorea-
dc.subject.keywordLDL-
dc.subject.keywordPractice guideline-
dc.subject.keywordRisk assessment-
dc.contributor.alternativeNameKim, Jung Sun-
dc.contributor.affiliatedAuthorKim, Jung-Sun-
dc.identifier.scopusid2-s2.0-85089379368-
dc.identifier.wosid000596724000018-
dc.citation.volume35-
dc.citation.number2-
dc.citation.startPage367-
dc.citation.endPage376-
dc.identifier.bibliographicCitationEndocrinology and Metabolism(대한내분비학회지), Vol.35(2) : 367-376, 2020-06-
dc.identifier.rimsid68062-
dc.type.rimsART-
dc.description.journalClass1-
dc.description.journalClass1-
dc.subject.keywordAuthorCholesterol-
dc.subject.keywordAuthorDyslipidemias-
dc.subject.keywordAuthorHydroxymethylglutaryl-CoA reductase inhibitors-
dc.subject.keywordAuthorKorea-
dc.subject.keywordAuthorLDL-
dc.subject.keywordAuthorPractice guideline-
dc.subject.keywordAuthorRisk assessment-
dc.subject.keywordPlusantilipemic agent-
dc.subject.keywordPlusfibric acid derivative-
dc.subject.keywordPlushydroxymethylglutaryl coenzyme A reductase inhibitor-
dc.subject.keywordPluslow density lipoprotein cholesterol-
dc.subject.keywordPlusomega 3 fatty acid-
dc.subject.keywordPlusadult-
dc.subject.keywordPlusArticle-
dc.subject.keywordPluscardiovascular disease assessment-
dc.subject.keywordPluscardiovascular risk-
dc.subject.keywordPluscohort analysis-
dc.subject.keywordPluscontrolled study-
dc.subject.keywordPluscross-sectional study-
dc.subject.keywordPlusdyslipidemia-
dc.subject.keywordPlusfemale-
dc.subject.keywordPlushealth care utilization-
dc.subject.keywordPlushigh risk population-
dc.subject.keywordPlushuman-
dc.subject.keywordPlusKorean (people)-
dc.subject.keywordPlusmajor clinical study-
dc.subject.keywordPlusmale-
dc.subject.keywordPlusmedical history-
dc.subject.keywordPlusmiddle aged-
dc.subject.keywordPlusobservational study-
dc.subject.keywordPlusphysician-
dc.subject.keywordPluspractice guideline-
dc.subject.keywordPlusprescription-
dc.subject.keywordPlusrisk assessment-
dc.subject.keywordPlussystematic coronary risk evaluation-
dc.type.docTypeArticle-
dc.description.isOpenAccessN-
dc.description.journalRegisteredClassscie-
dc.description.journalRegisteredClassscopus-
dc.description.journalRegisteredClasskci-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.